What we do Piramal Pharma Ltd is a global pharmaceutical company offering differentiated products and services across contract development, hospital generics, and consumer healthcare. |
Founded in 2,020 |
Market share Leader with strong global presence in CDMO, leading US hospital generics, and growing consumer healthcare segments. |
Problem solved Provides innovative pharma manufacturing, complex hospital generics, and trusted consumer wellness products addressing healthcare needs worldwide. |
Top clients or who we serve Serves global pharma and biotech companies, hospitals, and consumers across 100+ countries including India and international markets; B2B and B2C model. |
Key management Ms. Nandini Piramal (Chairperson) and Mr. Peter DeYoung (CEO) lead the company with significant industry experience. |
Our journey and innovations Founded in 2020, acquired pharma business from Piramal Enterprises, expanded biologics and peptide capabilities, listed in 2022, continuous new product launches. |
Where we operate Operates in over 100 countries with manufacturing in India, US, UK, Europe, Canada, and emerging markets. |
Top products or what we offer Integrated CDMO services, complex hospital generics like Sevoflurane and Intrathecal Baclofen, and consumer wellness brands including OTC products. |
Top brands Kenalog (hospital generics), Little’s, Lacto Calamine, CIR (consumer healthcare), strong CDMO portfolio with niche APIs and biologics. |
Raw materials needed Uses active pharmaceutical ingredients, biologics raw materials, specialty chemicals, sterile injectable components, and excipients. |
Raw materials supplier Sources raw materials globally from specialized chemical and biotech suppliers and partners. |
Recurring vs cyclical contribution Revenue mix includes recurring contract manufacturing and semi-cyclical generics and consumer healthcare sales. |
Our industry position Among top global CDMOs, market leader in US inhalation anesthesia and intrathecal therapy, robust consumer brand growth. |
Financial highlights FY23 consolidated revenue ₹7,081 Cr; EBITDA ₹853 Cr; net profit impacted by one-time items; FY26 nine-month revenue ₹6,117 Cr. |
Geographical revenue split ~22% revenue from India and ~78% from outside India in FY23, reflecting strong global focus. |
Order book Order inflows recovering post H1FY26 with significant RFPs in CDMO segment supporting future growth. |
Whats driving growth Improved biopharma funding, new product launches, manufacturing capacity expansion, and strategic acquisitions like Kenalog. |
Our future plans Investing US$90Mn in US facility expansions, growing biologics pipeline, increasing market penetration in CHG and consumer healthcare. |
Our green promise Committed to sustainability with science-based emission targets, zero OAIs in regulatory audits, and eco-conscious operations. |
Our people and values Employs 4,600+ employees globally with emphasis on diversity, ethics, and employee development. |
Key challenges ahead Managing cyclical biotech funding, regulatory delays in some markets, and macroeconomic uncertainties impacting growth. |
Interesting facts Zero USFDA OAI status despite 48 FDA inspections; first Indian CDMO to expand significantly in biologics and ADCs. |
Risks and strategy Risks from regulatory approvals, market competition mitigated by diversified portfolio, quality, and global footprint. |
